Therapeutic drug monitoring of immunosuppressant drugs.

@article{Johnston1999TherapeuticDM,
  title={Therapeutic drug monitoring of immunosuppressant drugs.},
  author={Atholl Johnston and David W Holt},
  journal={British journal of clinical pharmacology},
  year={1999},
  volume={47 4},
  pages={
          339-50
        }
}
  • A. Johnston, D. Holt
  • Published 1 April 1999
  • Medicine
  • British journal of clinical pharmacology
Individualizing a patient’s drug therapy to obtain the optimum balance between therapeutic efficacy and the occurrence of adverse events is the physician’s goal. However, achieving this goal is not always straight forward, being complicated by within and between patient variability in both pharmacokinetics and pharmacodynamics. In the early 1960s new analytical techniques became available allowing the measurement of the low drug concentrations seen in biological fluids during drug treatment… Expand
Gr upSM Therapeutic Drug Monitoring of Immunosuppressive Agents
The pharmacokinetics of the immunosuppressive drugs is complex and unpredictable. A narrow therapeutic index unique to each patient, as well as variable absorption, distribution, and elimination, areExpand
A Review on Therapeutic Drug Monitoring of Immunosuppressant Drugs
TLDR
Therapeutic monitoring of immunosuppressive therapy with cyclosporine is a critical requirement because of intra- and inter-patient variability of drug absorption, narrow therapeutic window and drug induced nephrotoxicity. Expand
Critical issues in therapeutic drug monitoring of antiretroviral drugs.
TLDR
The basis for TDM of antiretroviral drugs is summarized, the problems and prospects of this potential tool in the care for HIV-1–infected individuals are discussed, and there are still many questions to be answered. Expand
Critical Issues in Therapeutic Drug Monitoring of Antiretroviral Drugs
TLDR
The basis for TDM of antiretroviral drugs is summarized, the problems and prospects of this potential tool in the care for HIV-1–infected individuals are discussed, and many questions to be answered are answered before large-scale introduction of TDM can be justified. Expand
Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?
TLDR
Treatment with the immunosuppressive agent mycophenolate mofetil decreases the risk of rejection after renal transplantation and improves graft survival compared with azathioprine, and the role of therapeutic drug monitoring in increasing the therapeutic potential of MMF is unclear. Expand
Recent advances in therapeutic drug monitoring of immunosuppressive drugs
TLDR
The focus of this review is on the explanation, comparison and future outlook of the current analytical techniques for TDM of immunosuppressants. Expand
Therapeutic drug monitoring of immunosuppressant drugs in clinical practice.
TLDR
Current data on TDM of the following immunosuppressant drugs used in organ transplantation are summarized, and recent findings indicate that monitoring of drug levels 2 hours after dosing is a more sensitive predictor of outcome than trough (C0) monitoring. Expand
SIGNIFICANCE OF THERAPY MONITORING OF IMMUNOSUPPRESSIVE MEDICINES IN RENAL TRANSPLANTATION PATIENTS
Immunosuppressive medicines are characterized by specific pharmacokinetic profile which requires therapy monitoring by means of measuring their blood concentrations. Therapy monitoring, by means ofExpand
Methods for Clinical Monitoring of Cyclosporin in Transplant Patients
TLDR
The most common method of monitoring cyclosporin therapy involves monitoring pre-dose trough concentrations, but this method is less than ideal and comparative studies evaluating the impact of the specific monitoring method on definite patient outcomes are warranted. Expand
Variability in the pharmacokinetics of mycophenolic acid: Implications for therapeutic drug monitoring
TLDR
The aim of this thesis was to further explain the differences in the pharmacokinetics of MMF seen between renal transplant recipients, investigate the validity of these results in other populations, or when different formulations are used, and to describe the effects ofThese results on individualization of the MMF treatment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 119 REFERENCES
Therapeutic drug monitoring of antimetabolic cytotoxic drugs.
  • L. Lennard
  • Medicine
  • British journal of clinical pharmacology
  • 1999
TLDR
Therapeutic drug monitoring is not routinely used for cytotoxic agents because of the lack of established therapeutic concentration ranges, but methotrexate is the only agent which is routinely monitored in most treatment centres. Expand
Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring.
TLDR
The application of the multicenter randomized concentration-controlled clinical trial study design, and related study designs, as applied to older commonly used and monitored drugs and to two new immunosuppressant drugs, mycophenolate mofetil and tacrolimus are discussed. Expand
Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997).
TLDR
The goals of this meeting were to discuss, explore, and re-evaluate therapeutic monitoring standards for Neoralt with a focus on sparse-sampling-derived AUCs and singlepoint sampling methods and to provide the transplant community with suggestions concerning first steps on a pathway toward optimizing clinical outcomes with NeorALT. Expand
Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.
TLDR
The measurement of the pharmacodynamic response to Immunosuppressive drugs may provide not only a mechanism to predict the most appropriate dosing regimen, but also a viable alternative to traditional therapeutic drug monitoring, by assessing the overall state of immunosuppression. Expand
Pharmacodynamic monitoring of immunosuppressive drugs.
TLDR
AZA treatment of renal-transplant patients who exhibited an increase in thiopurine methyltransferase activity from time of transplantation resulted in fewer episodes of active rejection, and may provide an alternative approach to additional measurements of drug concentrations. Expand
Use of Therapeutic Drug Monitoring in Pharmacoeconomics
TLDR
Current literature with regard to pharmacoeconomics and cost-benefit analysis of TDM is discussed and the pharmacoeconomic benefits provided by this service to both in- and outpatients are discussed. Expand
Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach.
TLDR
For patients administered concomitant cyclosporine, ketoconazole, and diltiazem, the dosage of cyclosportine, if it is administered alone, should be 20% to achieve the same blood concentrations to allow safer drug concentration targeting of cyclOSporine after cardiothoracic transplantation. Expand
Therapeutic Drug Monitoring of Tacrolimus in Clinical Transplantation
TLDR
Therapeutic drug monitoring is important to avoid unnecessary toxicity, but the lower limit has not been fully defined, clearly, many patients with <5 ng/ml have excellent hepatic function, although careful monitoring continues. Expand
Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update.
TLDR
New derivatives of R APA, such as SDZ RAD, designed to overcome formulation problems associated with RAPA, while maintaining similar pharmacokinetics and in vivo activity, show promise as alternatives to RAP a. Expand
Concentration-Controlled Trials
TLDR
The measurement of drug concentrations rationalises the sometimes criticised intention-to-treat analysis, and the potential benefits of concentration-controlled trials can be realised in a wider arena, the practical problems must be addressed. Expand
...
1
2
3
4
5
...